ArticleScience advances2026

P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML.

Melanie L Goetz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.